SuperworthCorMedix PE ratio CRMD
Share price divided by earnings per share over the last twelve months, since 2025.
- Today, Oct 23, 2026
- 3.7×
- Peer median
- 12.8×
CorMedix's PE ratio is 3.7× as of Oct 23, 2026: a share price of $7.85 against $2.13 of earnings per share over the last twelve months.
The median for 10 large drugmakers of a similar size is 12.8×.
PE ratio over time
Year by year
| Year | End of year | Low | High |
|---|---|---|---|
| 2026 so far | 3.7× | 3.1× | 5.9× |
| 2025 | 6.1× | 4.7× | 66.2× |
Against its peers
Companies in Drug Manufacturers - General nearest CorMedix's size, closest first, today.
| Company | PE ratio |
|---|---|
| CRMDCorMedix | 3.7× |
| ZVRAZevra Therapeutics | 10.5× |
| IRWDIronwood Pharmaceuticals | 4.5× |
| PBYIPuma Biotechnology | 21.2× |
| COLLCollegium Pharmaceutical | 18.5× |
| ARVNArvinas | 45.6× |
| ABUSArbutus Biopharma | 5.4× |
| AMPHAmphastar Pharmaceuticals | 14.8× |
| OMEROmeros | 10.9× |
| PCRXPacira BioSciences | 104× |
| ANABAnaptysbio | 10.7× |
| Peer median | 12.8× |
Where CorMedix ranks
What the PE ratio tells you
Share price divided by earnings per share over the last twelve months. It is the price tag on a dollar of profit: 20× means you pay $20 for $1 of yearly earnings.
Blank while earnings are negative. A very low PE can mean the market expects profits to fall, so read it with growth and the company's own history.
More on CorMedix
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.